These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38797393)

  • 1. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.
    Cyske Z; Gaffke L; Rintz E; Wiśniewska K; Węgrzyn G; Pierzynowska K
    Neurochem Int; 2024 Sep; 178():105774. PubMed ID: 38797393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
    Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
    Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.
    den Hollander B; Le HL; Swart EL; Bikker H; Hollak CEM; Brands MM
    Mol Genet Metab; 2024; 143(1-2):108556. PubMed ID: 39116528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
    Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
    Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.
    Hoshikawa T; Watanabe T; Kotake M; Tiberghien N; Woo CK; Lewis S; Briston T; Koglin M; Staddon JM; Powney B; Schapira AHV; Takle AK
    Bioorg Med Chem Lett; 2023 Feb; 81():129130. PubMed ID: 36640928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.
    Williams D; Glasstetter LM; Jong TT; Chen T; Kapoor A; Zhu S; Zhu Y; Calvo R; Gehrlein A; Wong K; Hogan AN; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
    Proc Natl Acad Sci U S A; 2024 Oct; 121(42):e2406009121. PubMed ID: 39388267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
    Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
    Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
    Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
    JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Schapira AH
    Sci Rep; 2018 Jan; 8(1):1385. PubMed ID: 29362387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
    Yang SY; Taanman JW; Gegg M; Schapira AHV
    Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
    Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
    Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
    Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV
    Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
    Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.